Ispecimen Inc is a biotechnology company focused on enhancing the accessibility of biospecimens for research and clinical purposes. By leveraging advanced technology and an extensive network of biorepositories, Ispecimen facilitates the collection, management, and distribution of human biological samples, thereby accelerating medical research and development. Their platform aims to streamline the process for academia, pharmaceutical companies, and other organizations in need of high-quality biospecimens, ultimately contributing to advancements in personalized medicine and healthcare solutions. Read More
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Woburn, Massachusetts--(Newsfile Corp. - August 21, 2025) - iSpecimen Inc. (NASDAQ: ISPC), an online marketplace for human biospecimens, today announced...
iSpecimen Inc. (NASDAQ: ISPC ) closed yesterday at $1.16 per share with a market cap of just $6.4 million, based on 5.54 million shares outstanding. On paper, that number looks almost absurd for a company with working revenues, strategic partnerships, and now, a planned $200 million digital treasury.
WOBURN, MA / ACCESS Newswire / August 20, 2025 / A share price of $1.11. A $6.1 million market cap. Just 5.54 million shares outstanding. And a newly announced $200 million digital treasury. On paper, the disconnect between price and intrinsic value, let alone inherent potential, is hard to miss. But the real takeaway isn't just the contrast. It's what that contrast says about iSpecimen Inc. (NASDAQ:ISPC): a company with a functioning platform, measurable revenue, and real-world utility that remains miscategorized and underpriced by the market.(ISPC Share count and price data on 8/20/2025)
Woburn, Massachusetts--(Newsfile Corp. - August 7, 2025) - iSpecimen Inc. (NASDAQ: ISPC), a technology-enabled company modernizing the way human biospecimens...
That’s the story unfolding right now around iSpecimen Inc. (NASDAQ: ISPC), a microcap life sciences company that just made one of the boldest capital strategy announcements in recent memory. On Wednesday evening—after the market closed—iSpecimen unveiled its plan to establish a $200 million digital treasury focused on capital preservation, liquidity, and long-term growth.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
WOBURN, MA / ACCESS Newswire / August 8, 2025 / Occasionally, the market reacts in ways that don't immediately align with the news. That seems to be the case right now with iSpecimen Inc. (NASDAQ:ISPC), following a major strategic announcement that arrived after Wednesday's close.
WOBURN, MA / ACCESS Newswire / August 8, 2025 / Sometimes the market delivers gifts-but only to those paying attention. That's the story unfolding right now around iSpecimen Inc. (NASDAQ:ISPC), a microcap life sciences company that just made one of the boldest capital strategy announcements in recent memory. On Tuesday evening-after the market closed-iSpecimen unveiled its plan to establish a $200 million digital treasury focused on capital preservation, liquidity, and long-term growth.
Sometimes, the market gets it wrong. And when it does—when there’s a glaring disconnect between price and reality—savvy investors don’t just notice. They act.
WOBURN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to pay $500,000 for marketing and advertising services to be provided by IR Agency LLC, and the remainder for working capital and general corporate purposes.
WOBURN, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to pay $500,000 for marketing and advertising services to be provided by IR Agency LLC, and the remainder for working capital and general corporate purposes.
WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects a version issued on July 25, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen’s investor relations contact. KCSA is not currently affiliated with iSpecimen Inc. and was mistakenly included in the prior release. The corrected release is below in its entirety.
WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects the version issued on July 24, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen’s investor relations contact. KCSA is not currently affiliated with iSpecimen Inc. and was mistakenly included in the prior release. The corrected release is below in its entirety.
WOBURN, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.70 per share (the “Offering”). The aggregate gross proceeds to the Company from the Offering was approximately $4 million, before deducting underwriting discounts and commissions and other offering expenses.
